image header

News Releases

News Releases

Jul 21, 2020

ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Read more

Jul 16, 2020

ALX Oncology Announces Pricing of Initial Public Offering Read more

Jun 12, 2020

ALX Oncology Presents Preliminary Phase 1 Study Results of ALX148 in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Read more

May 29, 2020

ALX Oncology Presents Phase 1 Study Results of ALX148 in Combination with Standard Anti-Cancer Antibodies and Chemotherapy Regimens in Patients with Advanced Solid Tumors Read more

May 18, 2020

ALX Oncology to Present ALX148 Phase 1 Clinical Data at the Virtual 25th Congress of the European Hematology Association (EHA) Read more

May 14, 2020

ALX Oncology to Present ALX148 Phase 1 Study at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting Read more

May 4, 2020

ALX Oncology Announces Appointment of Rekha Hemrajani to Board of Directors Read more

Feb 18, 2020

ALX Oncology’s ALX148 Receives Two Fast Track Designations from FDA for the Treatment of Patients with Head and Neck Squamous Cell Carcinoma and Patients with Gastric or Gastroesophageal Junction Adenocarcinoma Read more

Feb 12, 2020

ALX Oncology Announces Closing of $105 Million Series C Financing Read more

Jan 7, 2020

ALX Oncology Appoints Peter S. García as Chief Financial Officer Read more